Hims & Hers down after FDA to restrict GLP-1 ingredients used in non-approved compounded drugs

Shares of Hims & Hers HIMS.N down 14.1% at $19.76 after the bell

U.S. FDA plans to restrict GLP-1 ingredients used in non-approved compounded drugs that companies such as Hims & Hers have been marketing as alternatives to authorized treatments, citing concerns over quality, safety and potential violations of federal law

FDA says it is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025

Meanwhile, U.S. Department of Health and Human Services' General Counsel, Mike Stuart, says he referred co to the DOJ for investigation over potential violations

Co on Thursday said it will begin offering copies of Novo Nordisk's NOVOb.CO new Wegovy pill at an introductory price of $49 per month, about $100 less than the brand name, prompting Novo Nordisk to say it would take legal action

HIMS has risen 34.3% in 2025